Overview

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Status:
Completed
Trial end date:
2024-05-04
Target enrollment:
Participant gender:
Summary
This study will investigate the Pharmacokinetic (PK) and safety of Budesonide and albuterol (BDA) metered dose inhaler (MDI) HFO and BDA MDI HFA in healthy male and female participants.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca